Related Experiment Video
Updated: May 31, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
Kimberly J Gorden1, Parvin Mesbah, Jill M Kolesar
1Division of Pharmacy Practice, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
Purpose:
The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-positive non-small cell lung cancer (NSCLC).
Summary:
EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clinical benefit compared to placebo. With the discovery of improved benefits in the approximately 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to standard chemotherapy with an improved toxicity profile. The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity.
Conclusion:
The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.
Insights
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show improved benefits for EGFR mutation-positive non-small cell lung cancer (NSCLC). These TKIs are recommended as a first-line therapy for advanced or metastatic EGFR-mutated NSCLC.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were initially studied in unselected non-small cell lung cancer (NSCLC) patients.
- A subset of NSCLC patients (approximately 16%) harbors EGFR mutations, leading to targeted therapeutic strategies.
Purpose of the Study:
- To review recent data supporting the use of EGFR tyrosine kinase inhibitors (TKIs) as a first-line treatment.
- Focus on EGFR mutation-positive non-small cell lung cancer (NSCLC).
Main Methods:
- Review of recent clinical trial data.
- Analysis of efficacy and toxicity profiles of EGFR TKIs.
Main Results:
- EGFR TKIs demonstrate comparable efficacy to standard chemotherapy in selected EGFR-mutated NSCLC populations.
- These inhibitors offer an improved toxicity profile compared to traditional chemotherapy.
- Common toxicities include rash and, rarely, fatal interstitial lung disease.
Conclusions:
- EGFR receptor TKIs are an effective first-line therapy for patients with advanced or metastatic EGFR-mutated NSCLC.
- Recommended for first-line treatment in this patient population.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...